Agree to disagree. It's more the point it is now trading at $250m market cap and they're just proposing they 'may' be able to cure it. 'May' being the key phrase. There have been many others before who thought the same - so much hype in itand still massive headwinds and risk. NEU may be able to resolve a whole myriad of neuro generative disorders from parkinson's to being 'aspirin for the brain' (assisting with ageing), including being phase 3 ready on Retts and Fragile X (orphan diseases thus allowing high drug pricing per patient per annum, versus say Biotron IF successful). I am interested to see their full results in due course but until then it is hard to justify the excitement except that it is targeting a '(un)sexy' indication. Anyway, point is that money flow and interest into the area is positive for Australian Biotech, rather than to debate point 3.
Cheers,
5x8's
Ann: Neuren and Lanstead agree to pause settlements for 120 days, page-73
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.97 |
Change
0.660(4.96%) |
Mkt cap ! $1.730B | |||
| Open | High | Low | Value | Volume |
| $13.50 | $14.04 | $12.96 | $4.125M | 302.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 72 | $13.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.97 | 274 | 4 |
View Market Depth
| Last trade - 11.58am 27/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |